MedTrace Logo

Montbretin Clinical Trial in Healthy Volunteers and Type 2 Diabetics

NCT05826054 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-10-15

No results posted yet for this study

Summary

The goal of this clinical trial is to test the investigational product, Montbretin A (MbA) in either individuals with type 2 diabetes (T2D) or healthy participants.

The main questions it aims to answer are:

* Safety of MbA
* Whether MbA has less side effects in comparison to other medications used to treat T2D

Participants will:

* Be given MbA at increasing amounts (10 mg to 300 mg) over a two-week treatment period, along with standardized meal;
* Undergo testing, including blood draws, blood sugar checks, electrocardiogram (ECG) and questionnaires.

Conditions

Interventions

DIETARY_SUPPLEMENT

Montbretin A

The investigational product is 95% pure montbretin A (MbA), a glycosylated acyl-flavonol isolated from the corms (bulbs) of the Crocosmia plant through hot water extraction. It is a potent and specific inhibitor of human pancreatic amylase (HPA).

Sponsors & Collaborators

  • Michael Smith Foundation for Health Research

    collaborator OTHER

  • Canadian Glycomics Network (GlycoNet) - Networks of Centres of Excellence (NCE)

    collaborator UNKNOWN

  • Robert Petrella

    lead OTHER

Principal Investigators

  • Robert Petrella, MD, PhD · University of British Columbia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05826054 on ClinicalTrials.gov